9 completed, 3 terminated, 1 withdrawn. 10 Phase 2, 9 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Terminated 3, Withdrawn 1 |
| Phase 1 | 9 | Completed 6, Terminated 3 |
| Phase 3 | 1 | Completed 1 |
Follow eprenetapopt: new trials by email Literature Review of eprenetapopt trials Research Report on eprenetapopt
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma Eprenetapopt, Venetoclax - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-11-30 | 2022-03-10 | |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT - Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Aprea Therapeutics | 1 | 2021-03-02 | 2025-03-17 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies APR-246 (eprenetapopt) + Pembrolizumab - Bladder Cancer, Gastric Cancer | Phase 1 / Phase 2 | Completed | Aprea Therapeutics | 40 | 2020-06-25 | 2025-05-13 |
| APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies APR-246, Venetoclax, Azacitidine - Myeloid Malignancy | Phase 1 | Completed | Aprea Therapeutics | 51 | 2019-12-13 | 2025-03-17 |
| APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant APR-246 - Acute Myeloid Leukemia or Myelodysplastic Syndromes | Phase 2 | Completed | Aprea Therapeutics | 33 | 2019-09-16 | 2025-03-17 |
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) APR-246 + azacitidine, Azacitidine - MDS | Phase 3 | Completed | Aprea Therapeutics | 154 | 2019-01-11 | 2025-03-18 |
| Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine APR-246, Azacitidine - Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations | Phase 1 / Phase 2 | Completed | Groupe Francophone des Myelodysplasies | 53 | 2018-09-15 | 2026-09-21 |
| A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma APR-246, Dabrafenib - Melanoma | Phase 1 / Phase 2 | Terminated | Aprea Therapeutics | 3 | 2018-01-18 | 2019-07-31 |
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD) - High-grade Serous Ovarian Cancer | Phase 2 | Completed | Aprea Therapeutics | 36 | 2017-07-31 | 2025-03-17 |
| Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms APR-246, Azacitidine - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 55 | 2017-05-18 | 2022-01-24 |
| A Study of APR-246 in Oesophageal Cancer APR-246 - Oesophageal Carcinoma | Phase 1 / Phase 2 | Terminated | Peter MacCallum Cancer Centre, Australia | 5 | 2017-04-11 | 2021-12-13 |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) - Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | Phase 1 / Phase 2 | Completed | Aprea Therapeutics | 247 | 2014-03-01 | 2025-03-17 |
| Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer APR-246 - Hematologic Neoplasms, Prostatic Neoplasms | Phase 1 | Completed | Aprea Therapeutics | 36 | 2009-05-01 | 2019-07-31 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Lymphoma, Mantle-Cell (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Ovarian Neoplasms (2) · Recurrence (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Neoplasm Metastasis (1)
Aprea Therapeutics (9) · Groupe Francophone des Myelodysplasies (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Peter MacCallum Cancer Centre, Australia (1)
United States (8) · Belgium (3) · France (3) · Spain (2) · Sweden (2) · United Kingdom (2) · Australia (1) · Germany (1) · Netherlands (1)
Joachim Gullbo, MD (2) · Ahmad Awada, PhD (1) · Asmita Mishra, MD, PhD (1) · Charlie Gourley, BSc, MB ChB, PhD, FRCP (1) · David Sallman, M.D. (1) · David Sallman, MD, PhD (1) · Joseph Kerger, MD (1) · Lara Lipton, MB.BS FRACP (1) · Pierre Fenaux (1)
PMID 33449813, PMID 33600210, PMID 35816664, PMID 36084396, PMID 36990622